HK1204605A1 - 用於治療癌症的功能化的噻吩並吲哚衍生物 - Google Patents

用於治療癌症的功能化的噻吩並吲哚衍生物

Info

Publication number
HK1204605A1
HK1204605A1 HK15104002.1A HK15104002A HK1204605A1 HK 1204605 A1 HK1204605 A1 HK 1204605A1 HK 15104002 A HK15104002 A HK 15104002A HK 1204605 A1 HK1204605 A1 HK 1204605A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
indole derivatives
thieno
functionalized
Prior art date
Application number
HK15104002.1A
Other languages
English (en)
Inventor
‧伯利亞
‧卡魯索
‧盧皮
‧奧西尼
‧薩爾薩
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1204605A1 publication Critical patent/HK1204605A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15104002.1A 2012-04-05 2015-04-24 用於治療癌症的功能化的噻吩並吲哚衍生物 HK1204605A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163437 2012-04-05
PCT/EP2013/056733 WO2013149946A1 (en) 2012-04-05 2013-03-28 Functionalized thieno-indole derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1204605A1 true HK1204605A1 (zh) 2015-11-27

Family

ID=48040232

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104002.1A HK1204605A1 (zh) 2012-04-05 2015-04-24 用於治療癌症的功能化的噻吩並吲哚衍生物

Country Status (8)

Country Link
US (1) US9561290B2 (zh)
EP (1) EP2836493B1 (zh)
JP (1) JP6251236B2 (zh)
CN (1) CN104203956B (zh)
ES (1) ES2686683T3 (zh)
HK (1) HK1204605A1 (zh)
RU (1) RU2632199C2 (zh)
WO (1) WO2013149946A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011358B (zh) * 2012-04-05 2020-05-05 内尔维阿诺医学科学有限公司 新的烷化剂
ES2738657T3 (es) * 2013-09-25 2020-01-24 Nerviano Medical Sciences Srl Derivados de tieno[2,3-e]indol como nuevos antitumorales
EP3597186B1 (en) 2015-01-05 2021-12-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Myc g-quadruplex stabilizing small molecules and their use
CN107660208B (zh) * 2015-03-20 2020-06-30 辉瑞公司 包含cti药效团的双功能细胞毒性剂
AU2016238551B2 (en) * 2015-03-20 2020-01-02 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
WO2017012924A1 (en) 2015-07-21 2017-01-26 Nerviano Medical Sciences S.R.L. Asymmetric process for the preparation of thieno-indoles derivatives
US10233212B2 (en) 2015-11-03 2019-03-19 Industrial Technology Research Institute Compounds, linker-drugs and ligand-drug conjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU930902A1 (ru) * 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
GB2344818A (en) * 1998-12-16 2000-06-21 Pharmacia & Upjohn Spa Anti-tumour thieno-indole derivatives
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
US20070037739A1 (en) * 2003-02-03 2007-02-15 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
US20050265925A1 (en) 2004-04-21 2005-12-01 Samuel Zalipsky Releasable linkage and compositions containing same
US7517903B2 (en) * 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
MX2008009956A (es) * 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
EP2303332B1 (en) 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
CN107011358B (zh) * 2012-04-05 2020-05-05 内尔维阿诺医学科学有限公司 新的烷化剂
US9790268B2 (en) * 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function

Also Published As

Publication number Publication date
RU2014143992A (ru) 2016-05-27
WO2013149946A1 (en) 2013-10-10
ES2686683T3 (es) 2018-10-19
JP2015512430A (ja) 2015-04-27
EP2836493A1 (en) 2015-02-18
US20150080316A1 (en) 2015-03-19
EP2836493B1 (en) 2018-06-20
CN104203956A (zh) 2014-12-10
RU2632199C2 (ru) 2017-10-03
CN104203956B (zh) 2017-03-29
JP6251236B2 (ja) 2017-12-20
US9561290B2 (en) 2017-02-07

Similar Documents

Publication Publication Date Title
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
HK1211982A1 (zh) 癌症治療
IL263781A (en) Combined treatment of ovarian cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
HK1214128A1 (zh) 癌症的治療
HK1204605A1 (zh) 用於治療癌症的功能化的噻吩並吲哚衍生物
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
GB201217892D0 (en) Treatment of cancer
HK1210023A1 (zh) 癌症治療
HK1204956A1 (zh) 癌症治療
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
IL233493A (en) Imidazopyridine derivatives for cancer treatment
GB201217890D0 (en) Treatment of cancer
GB201222563D0 (en) Cancer treatment
HK1202118A1 (zh) 治療癌症的哌嗪基衍生物
HK1200094A1 (zh) 免疫調節劑用於治療癌症的用途
IL233495A0 (en) Combination for cancer treatment
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201208296D0 (en) Treatment of cancer